Our data showed that although expression of cdk-4, cdk-6, and p27 was not affected by sorafenib, the levels of cyclin D1, cyclin cdk-2, and cyclin B1 in sorafenib-treated tumours were significantly reduced as compared with controls (P<0.05). This evidence concerns the gene CCNB1 and neoplasm.